
Welcome to Season 2 of BioBoss
BioBoss host John Simboli welcomes you to Season 2!
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

BioBoss host John Simboli welcomes you to Season 2!
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
John SimboliThanks, BioBoss subscribers around the world for making Season 1 of the podcast a success. And thanks to the biopharma founders and CEOs whose insights are the foundation of BioBoss. When I launched BioBoss in January, 2019 my goal was to give subscribers a seat at the table—an opportunity to listen in on my conversations with biopharma leaders, to hear firsthand how they wrestle with the challenge of creating clarity out of ambiguity.
John SimboliIn 2020 I invite BioBoss listeners to experience Season 2 of conversations with a new group of founders and CEOs. I'll also return to speak with some of my Season 1 guests to hear more from these leaders and the advances at their companies. Welcome to Season 2! I'm John Simboli. You're listening to BioBoss.
Nobody is credited on this episode yet.
Stephan Jackman, CEO of Alzamend Neuro, shares his insights about leadership in biopharma and how Alzamend is working to develop effective treatments for psychiatric disorders.
Ryan Beal, CEO of Dyve Biosciences, shares his insights about leadership in biopharma and how Dyve is working to deliver targeted pH modulation to treat a range of immunologic and oncologic diseases.
Haseeb Ahmad, CEO of Purespring Therapeutics, shares his insights about leadership in biopharma and how Purespring is working to help patients with kidney diseases to live fuller, healthier lives.
Lance Baldo, CEO of Beacon Therapeutics, shares his insights about leadership in biopharma and how Beacon is working to save and restore sight for people living with rare and prevalent ocular diseases.
Shaun Bagai, CEO of RenovoRX, shares his insights about leadership in biopharma and how RenovoRX is working to develop targeted oncology therapies and commercialize its FDA cleared drug delivery device.